Baxa Corporation And Carmel Pharma ab End Distribution Agreement For PhaSeal®

Englewood, CO - Baxa Corporation announced recently that its exclusive US distribution rights for the PhaSeal Products will end on December 31, 2005. The products' Swedish manufacturer, Carmel Pharma ab, has elected not to continue the agreement. Over the course of the agreement, Baxa more than tripled annual PhaSeal product sales. Today, PhaSeal is used in more than 300 leading cancer treatment facilities nationwide.

Carmel Pharma ab will establish a US headquarters to take over the marketing, sales and distribution activities for PhaSeal. Customers, wholesalers and Group Purchasing Organizations were notified of the distribution change effective January 1, 2006.

PhaSeal is the only documented, closed system for safe handling of hazardous drugs. Its unique design contains drug aerosols and prevents leakage from drug preparation to transport to administration and disposal. "Baxa is proud to have played an important role in raising the awareness of the risks of handling hazardous medications for leading US hospitals and clinics," notes Greg Baldwin, Baxa Chairman and CEO. "We are committed to doing our part to ensure a smooth transition for these customers."

Launched in the US in December, 2000, PhaSeal is used in nearly all of the top national cancer centers, including MD Anderson Cancer Center in Houston. A body of medical and research studies supports the use of closed systems such as PhaSeal to ensure the safety of nurses and technicians responsible for mixing and administering hazardous drugs.

SOURCE: Baxa Corporation